Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.

Amgen motion to delay Neupogen biosimilar denied

Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Rockpointe launches new compliance publication

Life Science Compliance Update will address growing compliance concerns in healthcare.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters